Financing

Debt Issuance Proceeds

AbbVie Debt Issuance Proceeds increased by 100.1% to $7.99B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.1%, from $3.99B to $7.99B.

Analysis

StatementCash Flow Statement
SectionFinancing
CategoryLeverage
SignalContext dependent
VolatilityVolatile
First reportedQ3 2015
Last reportedQ1 2026May 8, 2026

How to read this metric

An increase indicates successful access to capital markets for expansion or refinancing, while a decrease may suggest a focus on deleveraging or limited market access.

Detailed definition

This metric tracks the total cash proceeds received from the issuance of long-term or short-term debt instruments. It re...

Peer comparison

Large-cap companies frequently issue debt to optimize their cost of capital; peers monitor this to maintain investment-grade credit ratings.

Metric ID: debt_issuance

Historical Data

10 periods
 Q3 '21Q1 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q4 '24Q1 '25Q1 '26
Value$1.00B$2.00B$0.00$0.00$0.00$0.00$14.96B$2.00B$3.99B$7.99B
QoQ Change+100.0%-100.0%-86.6%+99.7%+100.1%
YoY Change-100.0%-73.3%+100.1%
Range$0.00$14.96B
CAGR+151.9%
Avg YoY Growth-24.4%
Median YoY Growth-73.3%
Current Streak2 quarters growth

Frequently Asked Questions

What is AbbVie's debt issuance proceeds?
AbbVie (ABBV) reported debt issuance proceeds of $7.99B in Q1 2026.
How has AbbVie's debt issuance proceeds changed year-over-year?
AbbVie's debt issuance proceeds increased by 100.1% year-over-year, from $3.99B to $7.99B.
What does debt issuance proceeds mean?
Cash received from taking on new debt.